Ulrike Szalay is the Founder and Executive Director of Canines-N-Kids Foundation
Did you know? Dogs and children spontaneously develop a number of similar cancers. In fact, cancer is the leading cause of disease-related childhood mortality in the U.S. and affects nearly half of all pet dogs too.
Although pediatric and veterinary cancer research have traditionally operated independently, recognition of profound clinical and biologic similarities has driven increasingly valuable collaboration among pediatric and veterinary clinicians and scientists. Scientific progress continues to demonstrate the impact that comparative research can have in accelerating the development of new treatments. The Canines-N-Kids Foundation, a nonprofit committed to finding a cure to the devastating cancers that both develop by advancing comparative oncology, is working to promote integration of research efforts benefiting both kids and pet dogs.
This year, Canines-N-Kids and Merck will co-host the Paws for a Cure Research Symposium in Boston from November 12-13. Thanks to significant support from title sponsor, the Petco Foundation, in partnership with the Blue Buffalo Foundation, as well as the Parker Institute for Cancer Immunotherapy, Boehringer Ingleheim, the American Cancer Society, the Rally Foundation and others, the symposium will convene experts to discuss advancing research in pediatric cancer treatments, including how to use comparative approaches to make progress.
The symposium is important because both children and canine companions spontaneously develop a number of cancers with remarkable similarities. The challenges inherent in designing and implementing pediatric oncology clinical trials for limited number of children with cancer, coupled with scant resources for conducting research on pediatric cancers, makes finding cures difficult for the roughly 16,000 children diagnosed in the US each year.
The integration of drug development in pediatric and pet populations has great potential to accelerate the discovery of novel, more effective, less toxic treatments for the cancers that plague children and dogs.
Can’t make it to Boston for Paws for a Cure? If you’re in the greater Washington DC, northern Virginia area, grab your sneakers, leash, pup and kids for the second Two By Four Race Against Childhood & Canine Cancer taking place on September 29th in Northern Virginia. The PhRMA Community Relations team has joined Canines-N-Kids as a Gold Ribbon sponsor of this timed 5k race and un-timed mile long Dog Jog/Fun Run to support cutting-edge research in the cancers that kids and pet dogs both develop. We welcome two and four legged athletes to help Crush Cancer @ Both Ends of the Leash, so register today!
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
New study: HPV vaccination helps prevent cervical cancer deaths
America's cancer research progress is real and worth protecting
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
Advancing patient care: A look at new medicines approved in 2025
CAREs 2025: Supporting community-based solutions that improve access to medicines
New analysis finds 340B hospitals push patients toward costly care to boost profits
Price setting policies put cancer gains in jeopardy
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Guest Perspective: Prioritize Innovative Care
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
The importance of partnership: A conversation with Takeda
The future of oncology R&D lies in policymakers’ hands
Showcasing the promise of biopharma at ASCO 2024
Championing cancer equity: Our drive for healthier AANHPI communities
The impact of innovative medicines: A caregiver's perspective
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
Three things to know about antibody drug conjugates
The IRA’s pill penalty threatens the future of oncology R&D
New Report: 1,600 cancer treatments and vaccines in clinical development
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
Watch: New video series spotlights advances in biopharmaceutical science
Between hope and despair: Improving cancer outcomes
New report shows high-impact R&D happens after cancer medicines are first approved
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
ASCO 2023: Protecting our progress in the fight against cancer
Highlights from ASCO 2023
IRA Impacts: Cancer treatment research and development
State policymakers can protect American innovation and help Americans live longer, healthier lives
ICYMI: Cancer death rate continues to decline due to treatment advances
Novel medicines approved in 2022 offer increased treatment options for patients
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
Protecting treatment advances for breast cancer
Key takeaways from ASCO's annual meeting
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Report: More than 500 medicines in development to treat disorders of the blood
4 things to know about biopharmaceutical efforts to fight cancer
New data show continued decline in death rates for cancer patients related to treatment advances
Recognizing National Immunization Awareness Month
Action needed to preserve the six protected classes
ICYMI: Cancer death rate continues decline due to advances in treatment
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
New report explores setbacks that bring future cancer success stories
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Cancer medicines cost twice as much at hospitals, study finds
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Spending on medicines grew less than one percent in 2017
Patients pay the price when hospitals mark up cancer medicines
A new era in cancer
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
Protect your health: Important disaster preparedness tips for Harvey and Irma
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
More than 240 immuno-oncology treatments in development to fight cancer
Medicines have significantly increased chances of cancer survival around the globe
ICYMI: Report highlights overall decrease in cancer death rates
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
The 20-year journey yielding a new weapon against cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
Saving kids and dogs from shared cancers
Cancer
Saving kids and dogs from shared cancers
Saving kids and dogs from shared cancers